Mapping chemotherapy-induced peripheral neuropathy phenotype and health-related quality of life in patients with cancer through exploratory analysis of multimodal assessment data

Wellbeing and Complementary Therapies in Breast Cancer Peripheral Neuropathy Care: A Scoping Review Focused on Foot Health

“…Most of the articles studied were published in the last 3 years ( n = 9) [ 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 ]. Six documents were published in the United States [ 18 , 25 , 26 , 27 , 28 , 29 ], and two were published in Turkey [ 17 , 21 ].…”

“…The rest ( n = 7) included samples with this type of tumor and people with other types of tumors. The most common chemotherapeutic agents were paclitaxel ( n = 10) [ 18 , 19 , 20 , 21 , 25 , 26 , 27 , 28 , 30 , 31 ] and paclitaxel and platinum ( n = 6) [ 16 , 17 , 22 , 23 , 27 , 29 ]. Only one article [ 24 ] included a wide variety of chemotherapy agents.…”

“…Concerning assessment tools, different scales and variables were used to evaluate CIPN, and no studies had this field as a study objective. The most widely used scales to evaluate CIPN were the National Cancer Institute Common Terminology Criteria for Adverse Events [ 16 , 17 , 18 , 20 , 23 ] ( n = 5) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire—Chemotherapy-Induced Peripheral Neuropathy, EORTC QLQ CIPN [ 19 , 22 , 23 , 25 , 30 ] ( n = 5). Other scales used were the Total Neuropathy Score-Clinical Version [ 16 , 22 ] and the EuroQol5 Dimension 5 Level (EQ-5D-5L) [ 24 ].…”

“…The most widely used scales to evaluate CIPN were the National Cancer Institute Common Terminology Criteria for Adverse Events [ 16 , 17 , 18 , 20 , 23 ] ( n = 5) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire—Chemotherapy-Induced Peripheral Neuropathy, EORTC QLQ CIPN [ 19 , 22 , 23 , 25 , 30 ] ( n = 5). Other scales used were the Total Neuropathy Score-Clinical Version [ 16 , 22 ] and the EuroQol5 Dimension 5 Level (EQ-5D-5L) [ 24 ]. Only one paper [ 31 ] used a questionnaire that included the person’s experience (Patient Neuropathy Questionnaire (PNQ)).…”

“…This article suggested that people who experience this side effect have worse overall QoL, functioning, and personal finances than those who are unaffected. Other scholars [ 16 , 24 , 28 ] studied different aspects related to CIPN and QoL, but this was not the main focus of their articles. Thus, the general study carried out by Hirose et al [ 24 ] showed that adverse events such as peripheral neuropathy, general malaise, edema of the extremities, and dry skin are significantly correlated with a decrease in QoL.…”